Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L01FF03	IMFINZI	BioTech	Durvalumab - 500mg/10ml	500mg/10ml	Injectable solution	L.L
L04AB02	IXIFI	BioTech	Infliximab - 100mg	100mg	Injectable powder for concentrate for solution	L.L
L03AB03	IMUKIN	BioTech	Interferon gamma - 100mcg/0.5ml	100mcg/0.5ml	Injectable suspension	6,348,312 L.L
A10AE01	INSULATARD	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
A10AE01	INSULATARD	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
L04AB02	INFLIXIREL	BioTech	Infliximab - 100mg	100mg	Injectable concentrate for solution	18,065,957 L.L
L04AB02	IXIFI	BioTech	Infliximab - 100mg	100mg	Injectable powder for concentrate for solution	23,911,751 L.L
L01FF03	IMFINZI	BioTech	Durvalumab - 500mg/10ml	500mg/10ml	Injectable solution	L.L
L01FF03	IMFINZI	BioTech	Durvalumab - 500mg/10ml	500mg/10ml	Injectable solution	227,939,689 L.L
L01FF03	IMFINZI	BioTech	Durvalumab - 500mg/10ml	500mg/10ml	Injectable solution	227,939,689 L.L
L01FF03	IMFINZI	BioTech	Durvalumab - 120mg/2.4ml	120mg/2.4ml	Injectable solution	59,776,110 L.L
L01FF03	IMFINZI	BioTech	Durvalumab - 120mg/2.4ml	120mg/2.4ml	Injectable solution	59,776,110 L.L
L01EA01	IMAREM	G	Imatinib (mesylate) - 400mg	400mg	Tablet, film coated	64,682,117 L.L
L01EA01	IMATINIB GP PHARM	G	Imatinib - 400mg	400mg	Tablet, coated	26,083,945 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 400mg	400mg	Tablet, film coated	36,046,335 L.L
L01EA01	IMATINIB SHILPA MESYLATE	G	Imatinib - 400mg	400mg	Tablet, film coated	21,518,059 L.L
L01EA01	IMATINIB SPC	G	Imatinib - 400mg	400mg	Tablet, film coated	62,161,280 L.L
L01EA01	IMATINIB GP PHARM	G	Imatinib - 100mg	100mg	Tablet, coated	26,083,945 L.L
N01AB06	ISOFLURANE HIKMA	G	Isoflurane -		Volatil liquid	1,583,046 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 100mg	100mg	Tablet, film coated	31,085,276 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 100mg	100mg	Tablet, film coated	16,144,207 L.L
L01EA01	IMATINIB SHILPA MESYLATE	G	Imatinib - 100mg	100mg	Tablet, film coated	14,396,132 L.L
L01EA01	IMATINIB SPC	G	Imatinib - 100mg	100mg	Tablet, film coated	29,473,181 L.L
A10BH05	INAGLIP	G	Linagliptin - 5mg	5mg	Tablet, film coated	1,242,606 L.L
P02CF01	IVERMECTINE BIOGARAN	G	Ivermectin - 3mg	3mg	Tablet	1,075,074 L.L
P02CF01	IVER	G	Ivermectin - 6mg	6mg	Tablet	431,373 L.L
P02CF01	IVERMECTIN BENTA	G	Ivermectin - 6mg	6mg	Tablet	784,548 L.L
P02CF01	IVERMECTIN BENTA	G	Ivermectin - 6mg	6mg	Tablet	470,985 L.L
N05CD08	IPNODIS MEDIS	G	Midazolam - 5mg/ml	5mg/ml	Injectable solution	565,758 L.L
N05CF04	INDUCTAL	G	Eszopiclone - 2mg	2mg	Tablet, film coated	1,411,035 L.L